Why Pharma Marketers and Publishers Should Invest in Header Bidding

For marketers and publishers, header bidding has become a hot topic in the pharma marketing industry, and for a good reason! Header bidding allows publishers to increase their ad revenue by giving buyers the opportunity to bid on inventory before it goes up for auction. This not only benefits publishers, but also gives buyers a chance to get their ads in front of potential customers earlier in the buying cycle.

For marketers, header bidding provides flexibility to integrate with multiple ad partner sources. Pharma marketers can test and compare multiple ad sources to see which delivers the best results. Header bidding also allows marketers to optimize their campaigns in real-time based on performance data.

In addition, header bidding can help marketers reach their target audience more effectively. Bypassing the traditional auction process and having direct access to inventory can help marketers reach their target audience more efficiently.

Header bidding has been shown to increase ad revenues by 30-50%, and with the current state of the economy, every little bit helps. If you’re a pharma marketer, header bidding is something you should definitely be paying attention to as it can help you reach your target audience earlier in the buying cycle, and increase your chances of getting your message seen by potential customers.

Overall, header bidding provides many benefits for both publishers and marketers. For pharma marketers, header bidding can provide a way to test multiple ad sources, optimize campaigns in real-time, and reach their target audience more effectively. Header bidding is changing the landscape of digital advertising, and pharma marketers should be taking advantage of this new opportunity.

Download the EHSX one-pager to get started: